![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Elbit Imaging Ltd (CE) | USOTC:EMITF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.85 | 0.00 | 01:00:00 |
During the meeting, new data will be presented from the NAM-NK and NiCord® programs, including the following1:
It should be noted that patient enrollment continues in the NAM-NK study of multiple myeloma and non-Hodgkin lymphoma (NHL), and in the study of severe aplastic anemia using NiCord.
Elbit holds approximately 63% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (approximately 41% on a fully diluted basis) which, in turn, holds approximately 2.7 million shares in Gamida, representing approximately 11% of Gamida's outstanding share capital (approximately 8% on a fully diluted basis).
About Gamida Cell Ltd.
Gamida is engaged in the development of products for curing cancer and rare bone marrow diseases. Gamida's products are currently being tested in clinical trials for patients with leukemia, lymph node cancer and non-malignant blood diseases. Gamida began a Phase III trial in patients with leukemia and lymph node cancer through NiCord, a drug that the FDA and EMA approved as orphan drug and which was recognized by the FDA as breakthrough treatment. It should be clarified that as of this date, the stage of development of Gamida's products has not yet been completed and there is no certainty that the products will be marketed on a commercial basis.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) land in India which is designated for sale (and which was initially designated for residential projects); and (iii) land in Eastern Europe which is designated for sale (and which was initially designated for development of commercial centers).
1 As part of Gamida's PR, reference was made to additional information about the studies through the TCT Meetings of ASBMT and CIBMTR website: https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/13531https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/13352https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/12685
For Further Information:Company ContactRon HadassiCEO and Chairman of the Board of DirectorsTel: +972-3-608-6048Fax: +972-3-608-6050ron@elbitimaging.com
1 Year Elbit Imaging (CE) Chart |
1 Month Elbit Imaging (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions